SSKN · Strata Skin Sciences, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · SSKN

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$30.70M	$33.56M	$33.36M	$36.16M	$29.98M	$23.09M
Cost of Revenue	$12.81M	$14.48M	$14.90M	$14.39M	$10.13M	$8.96M
Gross Profit	$17.88M	$19.08M	$18.46M	$21.77M	$19.85M	$14.13M
R&D	$421.0K	$883.0K	$1.32M	$1.03M	$1.43M	$1.27M
SG&A	$10.18M	$11.30M	$10.51M	$10.09M	$9.71M	$7.90M
Total Operating Expenses	$22.58M	$28.34M	$27.07M	$24.25M	$24.25M	$18.21M
D&A	$4.12M	$4.97M	$5.55M	$2.40M	$2.10M	$1.98M
Operating Income	($4.70M)	($9.26M)	($8.60M)	($4.65M)	($4.40M)	($4.08M)
Interest Expense	$1.96M	$2.11M	$1.64M	$926.0K	$211.0K	-
Income Tax	$12.0K	($170.0K)	($92.0K)	$63.0K	$34.0K	$275.0K
Net Income	($6.26M)	($10.09M)	($10.83M)	($5.55M)	($2.71M)	($4.41M)
EPS - Basic	($1.35)	($2.65)	($1.60)	($1.60)◇	-	($1.30)
EPS - Diluted	($1.35)	($2.65)	($3.10)	($1.60)◇	-	($1.30)

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$7.91M	$7.26M	$6.78M	$5.43M	$12.59M	$10.60M
Accounts Receivable	$4.12M	$5.25M	$4.44M	$4.47M	$3.43M	$2.94M
Inventory	$2.81M	$2.25M	$2.67M	$5.55M	$3.49M	$3.44M
Accounts Payable	$2.76M	$2.43M	$3.34M	$3.42M	$2.82M	$2.76M
Current Assets	$15.60M	$16.59M	$15.54M	$17.50M	$19.97M	$24.83M
Total Assets	$30.52M	$36.16M	$42.02M	$52.27M	$46.59M	$46.78M
Current Liabilities	$26.74M	$14.63M	$12.17M	$13.43M	$12.80M	$18.84M
Long-term Debt	$0	$15.19M	$15.04M	$7.48M	$7.32M	$1.05M
Total Liabilities	$27.61M	$31.18M	$29.33M	$30.44M	$21.18M	$20.89M
Stockholders' Equity	$2.91M	$4.97M	$12.69M	$21.83M	$25.41M	$25.89M
Retained Earnings	($254.41M)	($248.14M)	($238.06M)	($227.23M)	($221.68M)	($218.97M)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	($2.79M)	$188.0K	($519.0K)	($1.11M)	$1.51M	$2.10M
Investing Cash Flow	($1.47M)	($1.64M)	($5.02M)	($4.18M)	($7.13M)	($2.16M)
Financing Cash Flow	$3.58M	$1.93M	$6.86M	($500.0K)	$92.0K	$2.55M
CapEx	$1.47M	$1.64M	$5.02M	$3.55M	$3.65M	$26.0K
Free Cash Flow	($4.26M)	($1.45M)	($5.54M)	($4.66M)	($2.15M)	$2.07M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	58.3%	56.9%	55.3%	60.2%	66.2%	61.2%
Operating margin	-15.3%	-27.6%	-25.8%	-12.9%	-14.7%	-17.7%
EBITDA margin	-1.9%	-12.8%	-9.1%	-6.2%	-7.7%	-9.1%
Net margin	-20.4%	-30.1%	-32.5%	-15.3%	-9.0%	-19.1%
Free cash flow margin	-13.9%	-4.3%	-16.6%	-12.9%	-7.2%	9.0%
FCF / Net income	0.68	0.14	0.51	0.84	0.79	-0.47
R&D / Revenue	1.4%	2.6%	3.9%	2.8%	4.8%	5.5%
SG&A / Revenue	33.2%	33.7%	31.5%	27.9%	32.4%	34.2%
Effective tax rate	-	-	-	-	-	-
Return on assets	-20.5%	-27.9%	-25.8%	-10.6%	-5.8%	-9.4%
Return on equity	-215.3%	-202.9%	-85.4%	-25.4%	-10.6%	-17.0%
Return on invested capital	-127.7%	-36.3%	-24.5%	-12.5%	-10.6%	-12.0%
Liquidity
Current ratio	0.58	1.13	1.28	1.30	1.56	1.32
Quick ratio	0.48	0.98	1.06	0.89	1.29	1.14
Cash ratio	0.30	0.50	0.56	0.40	0.98	0.56
Leverage
Debt / Equity	0.00	3.06	1.19	0.34	0.29	0.04
Debt / Assets	0.00	0.42	0.36	0.14	0.16	0.02
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-2.4x	-4.4x	-5.2x	-5.0x	-20.9x	-
Equity multiplier	10.50	7.27	3.31	2.39	1.83	1.81
Liabilities / Assets	0.90	0.86	0.70	0.58	0.45	0.45
Efficiency
Asset turnover	1.01	0.93	0.79	0.69	0.64	0.49
Inventory turnover	4.55	6.45	5.57	2.59	2.90	2.60
Days sales outstanding	49d	57d	49d	45d	42d	47d
Days inventory outstanding	80d	57d	65d	141d	126d	140d
Days payable outstanding	79d	61d	82d	87d	102d	113d
Cash conversion cycle	51d	52d	32d	99d	66d	74d
Valuation
P / E	-	-	-	-	-	-
P / B	2.0x	2.2x	15.0x	12.6x	-	19.5x
P / S	0.2x	0.3x	5.7x	7.6x	-	21.8x
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	-8.5%	0.6%	-7.8%	20.6%	29.8%	-26.9%
Revenue CAGR (3y)	-5.3%	3.8%	13.0%	4.6%	-1.9%	-9.8%
Revenue CAGR (5y)	5.9%	1.2%	1.0%	2.8%	-1.1%	4.5%
Gross profit growth (YoY)	-6.3%	3.4%	-15.2%	9.7%	40.4%	-30.3%
Operating income growth (YoY)	49.2%	-7.6%	-85.1%	-5.6%	-8.0%	-35.4%
Net income growth (YoY)	37.9%	6.9%	-95.2%	-105.1%	38.7%	-16.4%
EPS growth (YoY)	49.1%	14.5%	-93.7%	-	-	-1081.8%
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	-194.3%	73.9%	-18.8%	-117.2%	-	-
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	-41.5%	-60.8%	-41.9%	-14.1%	-1.8%	-9.6%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$30.70M total

Dermatology Recurring Procedures$21.48M · 70.0%

Dermatology Procedures Equipment$9.22M · 30.0%

Geographic

$26.73M total

US$19.57M · 73.2%

CN$3.35M · 12.6%

Geographic Distribution Other Foreign$1.91M · 7.1%

Middle East$1.90M · 7.1%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

-6.75

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9

Neutral

✗Net income positive
✗Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
✓Long-term debt decreased
✗Current ratio improved
✗No share dilution
✓Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Surgical & Medical Instruments & Apparatus

Company	Revenue (last FY)	Net margin	ROE
BSX	$20.07B	14.4%	12.0%
LMAT	$249.60M	23.1%	14.7%
TNDM	$1.01B	-20.2%	-131.9%
SYK	$25.12B	12.9%	14.5%
MMM	$24.95B	13.0%	69.1%

Comparing STRATA Skin Sciences against the 5 most active filers in the same SIC group.

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.